期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小剂量沙利度胺和泼尼松联合达那唑显著改善原发性骨髓纤维化所致贫血 被引量：16

Comments on “Thalidomide plus prednisone with or without danazol therapy in myelofibrosis:a retrospective analysis of incidence and durability of anemia response”
原文传递
导出
摘要 本文最初发表于2018年《Blood Cancer J》杂志上,文章题录为:Luo X,Xu Z,Li B,et al.Thalidomide plus prednisone with or without danazol therapy in myelofibrosis:a retrospective analysis of incidence and durability of anemia response[J].Blood Cancer J,2018,8:9-13。本研究表明,沙利度胺和泼尼松联合达那唑治疗原发性骨髓纤维化贫血有效率显著高于沙利度胺和泼尼松组,而不增加不良反应发生率。且在红细胞输注依赖的患者中,这种治疗优势依然存在。这一研究结果为临床治疗原发性骨髓纤维化患者的血细胞减少提供了一个更好的治疗策略。
作者 徐泽锋 肖志坚
机构地区 中国医学科学院血液病医院(血液学研究所)
出处 《临床血液学杂志》 CAS 2018年第6期815-819,共5页 Journal of Clinical Hematology
关键词 原发性骨髓纤维化 贫血 沙利度胺 泼尼松 达那唑 primary myelofibrosis anemia thalidomide prednisone danazol
分类号 R551.3 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献3

二级参考文献24

  • 1Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diag- nosis and management of myelofibrosis [J]. Br J Haematol, 2012,158(4):453-471.
  • 2Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia [J]. Blood, 2003, 101(7): 2534-2541.
  • 3Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with rnyeloid rnetaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT) [J]. Blood, 2006, 108(5):1497-1503.
  • 4Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: develop- ment of a comprehensive grading system for the adverse effects of cancer treatment[J]. Semin Radiat Oncol, 2003, 13(3) : 176- 181.
  • 5Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) [J]. Blood,2010,115 (9):1703-1708.
  • 6Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis [J]. Expert Opin Pharmacother, 2011, 12 (10): 1597-1611.
  • 7Stein BL, Moliterno AR. Primary myelofibrosis and the myelo- proliferative neoplasms: the role of individual variation [J]. JAMA, 2010, 303(24): 2513-2518.
  • 8Cervantes F, ANarez-Larran A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofi- brosis with myeloid metaplasia: long-term results in 30 patients [J]. Br J Haematol, 2005, 129(6):771-775.
  • 9Mesa R.A, Verstovsek S, Cervantes F, et al. Primary myelofibro- sis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) [J]. Leuk Res, 2007, 31 (6):737- 740. doi: 10.1016/j.leukres.2006.12.002.
  • 10Barosi G, Rosti V, Vannucchi AM. Therapeutic approaches in myelofibrosis[ J ]. Expert Opin Pharmacother, 2011, 12 (10): 1597-1611. doi: 10.1517/14656566.2011.568939.

共引文献53

同被引文献46

引证文献16

二级引证文献88

临床血液学杂志
2018年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部